BRIEF—Positive data for Scynexis' fungal infection therapy

New Jersey, USA-based Scynexis has announced positive results from an interim efficacy analysis of the Phase III FURI study evaluating oral ibrexafungerp for people with difficult-to-treat fungal infections.

Previously known as MK-3118 and developed with fellow New Jersey firm Merck & Co under the terms of a 2002 agreement, Scynexis regained rights to the candidate in 2013 when its partner  backed out.

The study evaluates the therapy against mucocutaneous and invasive infections that do not respond to standard of care. The analysis shows clinical benefits in 17 out of 20 people, with 11 achieving a complete or partial response.

The firm says it plans to file for approval in the USA through the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).